[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Jazz Pharma Plc (JAZZ)

Jazz Pharma Plc (JAZZ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 14,112,692
  • Shares Outstanding, K 62,818
  • Annual Sales, $ 4,268 M
  • Annual Income, $ -356,150 K
  • EBIT $ 462 M
  • EBITDA $ 1,159 M
  • 60-Month Beta 0.32
  • Price/Sales 3.34
  • Price/Cash Flow 13.81
  • Price/Book 3.11

Options Overview Details

View History
  • Implied Volatility 33.75% (+1.81%)
  • Historical Volatility 26.16%
  • IV Percentile 27%
  • IV Rank 18.10%
  • IV High 69.53% on 08/05/25
  • IV Low 25.84% on 11/24/25
  • Expected Move (DTE 25) 13.77 (6.10%)
  • Put/Call Vol Ratio 0.10
  • Today's Volume 33
  • Volume Avg (30-Day) 114
  • Put/Call OI Ratio 0.93
  • Today's Open Interest 4,315
  • Open Int (30-Day) 7,018
  • Expected Range 212.15 to 239.69

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $5.06
  • Number of Estimates 4
  • High Estimate $5.27
  • Low Estimate $4.64
  • Prior Year $-9.07
  • Growth Rate Est. (year over year) +155.79%

Price Performance

See More
Period Period Low Period High Performance
1-Month
220.74 +2.35%
on 06/18/26
242.00 -6.64%
on 05/26/26
-13.91 (-5.80%)
since 05/22/26
3-Month
180.68 +25.04%
on 03/24/26
243.32 -7.15%
on 05/22/26
+45.30 (+25.08%)
since 03/20/26
52-Week
105.00 +115.16%
on 08/06/25
243.32 -7.15%
on 05/22/26
+118.41 (+110.14%)
since 06/20/25

Most Recent Stories

More News
Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies

The collaboration includes $56 million in upfront payments to AbCellera and up to $792 million in potential option fees and milestone payments for any program Jazz exercises options to develop

ABCL : 5.74 (+3.80%)
JAZZ : 225.92 (+0.56%)
Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies

The collaboration includes $56 million in upfront payments to AbCellera and up to $792 million in potential option fees and milestone payments for any program Jazz exercises its option to develop ...

ABCL : 5.74 (+3.80%)
JAZZ : 225.92 (+0.56%)
Jazz Pharmaceuticals Delivers Extensive Late-Breaking Data at SLEEP 2026, Demonstrating Real-World Impact of Xywav® (calcium, magnesium, potassium, and sodium oxybates) on Patient Outcomes Across Narcolepsy and Idiopathic Hypersomnia

New late-breaking data presentations underscore Jazz's significant progress in advancing holistic understanding of narcolepsy and idiopathic hypersomnia, including novel real-world evidence of meaningful...

JAZZ : 225.92 (+0.56%)
Jazz Pharmaceuticals (JAZZ): Buy, Sell, or Hold Post Q1 Earnings?

Jazz Pharmaceuticals (JAZZ): Buy, Sell, or Hold Post Q1 Earnings?

JAZZ : 225.92 (+0.56%)
Pharmaceuticals Stocks Q1 Recap: Benchmarking Jazz Pharmaceuticals (NASDAQ:JAZZ)

Pharmaceuticals Stocks Q1 Recap: Benchmarking Jazz Pharmaceuticals (NASDAQ:JAZZ)

JAZZ : 225.92 (+0.56%)
Jazz Pharmaceuticals Provides Update on Zepzelca® (lurbinectedin) Phase 3 LAGOON Trial in Second-Line Small Cell Lung Cancer

For U.S. media and investors only

JAZZ : 225.92 (+0.56%)
3 Unpopular Stocks We Find Risky

3 Unpopular Stocks We Find Risky

RDW : 13.02 (-9.27%)
BFH : 103.68 (+1.24%)
JAZZ : 225.92 (+0.56%)
Jazz Pharmaceuticals to Present Comprehensive Data at SLEEP 2026 Highlighting Broad Treatment Effects of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for People with Narcolepsy and Idiopathic Hypersomnia

Twenty-one abstracts, including 11 late-breaking abstracts, underscore Jazz's unwavering commitment to advancing the treatment of narcolepsy and idiopathic hypersomnia

JAZZ : 225.92 (+0.56%)
3 Healthcare Stocks We Think Twice About

3 Healthcare Stocks We Think Twice About

OMCL : 38.68 (-0.95%)
PNTG : 33.63 (+0.57%)
JAZZ : 225.92 (+0.56%)
Phase 3 HERIZON-GEA-01 Results Published in The New England Journal of Medicine Show Durable and Consistent Survival Benefit with Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA

Expanded safety, subgroup, progression-free survival sensitivity and subsequent therapy analyses further characterize the consistency and durability of outcomes observed with zanidatamab-containing...

JAZZ : 225.92 (+0.56%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Jazz Pharmaceuticals is a specialty biopharmaceutical company with a focus in the areas of neuroscience & oncology. It derives the majority of its revenues from its sleep disorder drugs' Xywav & Xyrem. Both drugs are approved for treating cataplexy & excessive daytime sleepiness in narcolepsy patients....

See More

Key Turning Points

3rd Resistance Point 231.34
2nd Resistance Point 229.60
1st Resistance Point 227.76
Last Price 225.92
1st Support Level 224.18
2nd Support Level 222.43
3rd Support Level 220.59

See More

52-Week High 243.32
Last Price 225.92
Fibonacci 61.8% 190.48
Fibonacci 50% 174.16
Fibonacci 38.2% 157.84
52-Week Low 105.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.